Skip to main content
. 2015 May 1;10(5):e0126413. doi: 10.1371/journal.pone.0126413

Fig 4. High prominence:Low prominence ratios over time.

Fig 4

(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.